JAK激酶抑制剂乌帕替尼治疗化脓性汗腺炎的真实世界安全性及临床反应：一项回顾性队列研究 - Suppr

Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.

作者信息

Kozera Emily, Flora Akshay, Frew John W

机构信息

Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia.

Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia; University of New South Wales, Sydney, Australia.

出版信息

J Am Acad Dermatol. 2022 Dec;87(6):1440-1442. doi: 10.1016/j.jaad.2022.07.047. Epub 2022 Aug 4.

DOI:10.1016/j.jaad.2022.07.047

PMID:35934210

Abstract

摘要

相似文献

Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.

J Am Acad Dermatol. 2022 Dec;87(6):1440-1442. doi: 10.1016/j.jaad.2022.07.047. Epub 2022 Aug 4.

A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.

Int Immunopharmacol. 2024 Jan 25;127:111435. doi: 10.1016/j.intimp.2023.111435. Epub 2023 Dec 26.

Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.

J Drugs Dermatol. 2023 Dec 1;22(12):1183-1190. doi: 10.36849/JDD.7500.

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature.

Medicina (Kaunas). 2023 Apr 20;59(4):801. doi: 10.3390/medicina59040801.

Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib.

Front Immunol. 2024 Aug 5;15:1432233. doi: 10.3389/fimmu.2024.1432233. eCollection 2024.

Management of Hidradenitis Suppurativa Using Janus Kinase Inhibitors: An Evidence-Based Review.

J Cutan Med Surg. 2023 Nov;27(6):665-667. doi: 10.1177/12034754231211794. Epub 2023 Nov 10.

Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.

J Am Acad Dermatol. 2024 May;90(5):1031-1034. doi: 10.1016/j.jaad.2024.01.004. Epub 2024 Jan 9.

Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.

Med Lett Drugs Ther. 2019 Nov 18;61(1585):183-185.

Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa.

J Eur Acad Dermatol Venereol. 2024 Feb;38(2):e139-e141. doi: 10.1111/jdv.19483. Epub 2023 Sep 13.

Rapid Attenuation of B-Cell and IFN-γ-Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa.

J Invest Dermatol. 2024 Feb;144(2):416-419.e5. doi: 10.1016/j.jid.2023.07.023. Epub 2023 Aug 25.

引用本文的文献

A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment.

Orphanet J Rare Dis. 2025 May 18;20(1):236. doi: 10.1186/s13023-025-03720-5.

Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa.

JAAD Case Rep. 2024 Dec 16;56:74-76. doi: 10.1016/j.jdcr.2024.12.008. eCollection 2025 Feb.

European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.

J Eur Acad Dermatol Venereol. 2025 May;39(5):899-941. doi: 10.1111/jdv.20472. Epub 2024 Dec 19.

Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.

J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.

Australasian hidradenitis suppurativa management guidelines.

Australas J Dermatol. 2025 Mar;66(2):75-89. doi: 10.1111/ajd.14388. Epub 2024 Nov 22.

Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?

J Pers Med. 2024 Jul 22;14(7):775. doi: 10.3390/jpm14070775.

Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution.

Antibiotics (Basel). 2024 Mar 17;13(3):268. doi: 10.3390/antibiotics13030268.

Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib.

Cureus. 2024 Jan 16;16(1):e52377. doi: 10.7759/cureus.52377. eCollection 2024 Jan.

Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts.

Adv Healthc Mater. 2024 May;13(12):e2303256. doi: 10.1002/adhm.202303256. Epub 2024 Jan 26.

New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.

J Dermatol. 2024 Feb;51(2):172-179. doi: 10.1111/1346-8138.17031. Epub 2023 Nov 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.

作者信息

Kozera Emily, Flora Akshay, Frew John W

机构信息

Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia.

出版信息

J Am Acad Dermatol. 2022 Dec;87(6):1440-1442. doi: 10.1016/j.jaad.2022.07.047. Epub 2022 Aug 4.

DOI:10.1016/j.jaad.2022.07.047

PMID:35934210

Abstract

摘要

相似文献

Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.

J Am Acad Dermatol. 2022 Dec;87(6):1440-1442. doi: 10.1016/j.jaad.2022.07.047. Epub 2022 Aug 4.

A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.

Int Immunopharmacol. 2024 Jan 25;127:111435. doi: 10.1016/j.intimp.2023.111435. Epub 2023 Dec 26.

Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.

J Drugs Dermatol. 2023 Dec 1;22(12):1183-1190. doi: 10.36849/JDD.7500.

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature.

Medicina (Kaunas). 2023 Apr 20;59(4):801. doi: 10.3390/medicina59040801.

Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib.

Front Immunol. 2024 Aug 5;15:1432233. doi: 10.3389/fimmu.2024.1432233. eCollection 2024.

Management of Hidradenitis Suppurativa Using Janus Kinase Inhibitors: An Evidence-Based Review.

J Cutan Med Surg. 2023 Nov;27(6):665-667. doi: 10.1177/12034754231211794. Epub 2023 Nov 10.

Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.

J Am Acad Dermatol. 2024 May;90(5):1031-1034. doi: 10.1016/j.jaad.2024.01.004. Epub 2024 Jan 9.

Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.

Med Lett Drugs Ther. 2019 Nov 18;61(1585):183-185.

Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa.

J Eur Acad Dermatol Venereol. 2024 Feb;38(2):e139-e141. doi: 10.1111/jdv.19483. Epub 2023 Sep 13.

Rapid Attenuation of B-Cell and IFN-γ-Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa.

J Invest Dermatol. 2024 Feb;144(2):416-419.e5. doi: 10.1016/j.jid.2023.07.023. Epub 2023 Aug 25.

引用本文的文献

A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment.

Orphanet J Rare Dis. 2025 May 18;20(1):236. doi: 10.1186/s13023-025-03720-5.

Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa.

JAAD Case Rep. 2024 Dec 16;56:74-76. doi: 10.1016/j.jdcr.2024.12.008. eCollection 2025 Feb.

European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.

J Eur Acad Dermatol Venereol. 2025 May;39(5):899-941. doi: 10.1111/jdv.20472. Epub 2024 Dec 19.

Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.

J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.

Australasian hidradenitis suppurativa management guidelines.

Australas J Dermatol. 2025 Mar;66(2):75-89. doi: 10.1111/ajd.14388. Epub 2024 Nov 22.

Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?

J Pers Med. 2024 Jul 22;14(7):775. doi: 10.3390/jpm14070775.

Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution.

Antibiotics (Basel). 2024 Mar 17;13(3):268. doi: 10.3390/antibiotics13030268.

Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib.

Cureus. 2024 Jan 16;16(1):e52377. doi: 10.7759/cureus.52377. eCollection 2024 Jan.

Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts.

Adv Healthc Mater. 2024 May;13(12):e2303256. doi: 10.1002/adhm.202303256. Epub 2024 Jan 26.

New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.

J Dermatol. 2024 Feb;51(2):172-179. doi: 10.1111/1346-8138.17031. Epub 2023 Nov 27.

Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献